Wie ist das Verhältnis von ASG zu PS im Vergleich zu anderen Unternehmen?

ASG is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (29.1x).

Wie ist das Verhältnis von ASG zu PS im Vergleich zu anderen Unternehmen der Branche CA Medical Equipment?

ASG is good value based on its Price-To-Sales Ratio (1.3x) compared to the North American Medical Equipment industry average (3.4x).

Wie hoch ist das PS Verhältnis von ASG im Vergleich zu seinem fairen PS Verhältnis? Dies ist das erwartete PS Verhältnis unter Berücksichtigung des prognostizierten Gewinnwachstums des Unternehmens, der Gewinnspannen und anderer Risikofaktoren.

Insufficient data to calculate ASG's Price-To-Sales Fair Ratio for valuation analysis.

Wie hoch ist der faire Preis von ASG, wenn man die zukünftigen Cashflows betrachtet? Für diese Schätzung verwenden wir ein Discounted-Cashflow-Modell.

Insufficient data to calculate ASG's fair value for valuation analysis.

Wie sieht die 12-Monats-Prognose der Analysten aus und haben wir statistisches Vertrauen in das Konsenskursziel?

Insufficient data to show price forecast.

Aurora Spine (TSXV:ASG) - Aktienkurs, Nachrichten und Analyse

ASG Aktienübersicht

Die Aurora Spine Corporation ist über ihre Tochtergesellschaft Aurora Spine, Inc. in der Entwicklung und dem Vertrieb von minimal-invasiven Systemen und Geräten zur Fusion der Wirbelsäule in Kanada tätig.

Über das Unternehmen

ASG grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Earnings have declined by 8% per year over past 5 years

Has less than 1 year of cash runway

Does not have a meaningful market cap (CA$30M)

Volatile share price over the past 3 months compared to the Canadian market

Aurora Spine Corporation Wettbewerber

Nanalysis Scientific

TSXV:NSCI

CA$40.7m

NuGen Medical Devices

TSXV:NGMD

CA$20.7m

Conavi Medical

TSXV:CNVI

CA$51.1m

MedX Health

TSXV:MDX

CA$16.2m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Aurora Spine
Historische Aktienkurse
Aktueller Aktienkurs	CA$0.39
52-Wochen-Hoch	CA$0.47
52-Wochen-Tief	CA$0.22
Beta	0.63
11 Monat Veränderung	39.29%
3 Monate Veränderung	52.94%
1 Jahr Veränderung	-1.27%
33 Jahre Veränderung	9.86%
5 Jahre Veränderung	-1.27%
Veränderung seit IPO	-71.11%

Aktuelle Nachrichten und Updates

Recent updates

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

Oct 19

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Oct 16

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Aug 14

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Aktionärsrenditen

	ASG	CA Medical Equipment	CA Markt
7D	1.3%	-3.0%	-1.5%
1Y	-1.3%	-7.7%	21.1%

Rendite im Vergleich zur Industrie: ASG exceeded the Canadian Medical Equipment industry which returned -7.7% over the past year.

Rendite vs. Markt: ASG underperformed the Canadian Market which returned 21.1% over the past year.

Preisvolatilität

Is ASG's price volatile compared to industry and market?
ASG volatility
ASG Average Weekly Movement	14.7%
Medical Equipment Industry Average Movement	13.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiler Aktienkurs: ASG's share price has been volatile over the past 3 months compared to the Canadian market.

Volatilität im Zeitverlauf: ASG's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2013	n/a	Trent Northcutt	www.aurora-spine.com

Die Aurora Spine Corporation ist über ihre Tochtergesellschaft Aurora Spine, Inc. in der Entwicklung und dem Vertrieb von minimalinvasiven interspinalen Fusionssystemen und -geräten in Kanada tätig. Das Unternehmen bietet interspinöse Lendenwirbelfusionssysteme wie ZIP, ZIP ULTRA, ZIP LP und ZIP-51 für Patienten mit degenerativen Bandscheibenerkrankungen sowie Ti-Coated Polyetheretherketon Interbody Cages an, die für Abstand und Stabilität zwischen den Wirbeln sorgen, während der Knochen wächst, um den Fusionsprozess abzuschließen. Darüber hinaus bietet das Unternehmen steril verpackte, mit Titanplasmaspray beschichtete Wirbelsäuleninfusionsimplantate für das Knochenwachstum sowie Interbody-Produkte wie EOS, VOX, Echo, Echo SD und EchoXL für den lumbalen Bereich der Wirbelsäule und Discovery für zervikale Verfahren.

Aurora Spine Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Aurora Spine im Vergleich zum Marktanteil des Unternehmens?
ASG grundlegende Statistiken
Marktanteil	CA$30.19m
Gewinn(TTM)	-CA$886.94k
Umsatz(TTM)	CA$23.59m

1.3x

Kurs-Umsatz-Verhältnis

-34.0x

Kurs-Gewinn-Verhältnis

Ist ASG zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ASG Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$16.90m
Kosten der Einnahmen	US$6.70m
Bruttogewinn	US$10.21m
Sonstige Ausgaben	US$10.84m
Umsatz	-US$635.51k

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.0082
Bruttomarge	60.39%
Nettogewinnspanne	-3.76%
Schulden/Eigenkapital-Verhältnis	53.1%

Wie hat sich ASG auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ASG Aktienübersicht

Belohnungen

Risikoanalyse

Aurora Spine Corporation Wettbewerber

TSXV:NSCI

CA$40.7m

TSXV:NGMD

CA$20.7m

TSXV:CNVI

CA$51.1m

TSXV:MDX

CA$16.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Recent updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Erträge & Einnahmen